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2
medicinal products, plastics and polymers, sanitary paper,
dyes, and lacquers as well as plaster and purification means.
Patent application publication WO 80/02378 discloses a
carrier manufactured from an absorbable plastic, ethylene/
vinyl acetate, collagen, or albumin material for promoting
vascularization and endothelial activity in mammals. The

WOUND CARE
REFERENCE TO RELATED APPLICATION

This is a continuation of U.S. application Ser. No. 12/683,
244, filed Jan. 6, 2010, now U.S. Pat. No. 8,173,154 the entire

disclosure of which is incorporated by reference.

carrier is in the form of a tube, sheet, thread, or net, and can,

STATEMENT OF GOVERNMENT INTEREST
10

This invention was made with Government support under
Department of the Army contract W81XWH-08-1-7065. The
Government may have certain rights in the invention.
FIELD OF THE INVENTION

for example, be laid over skin ulcers.
There is a continuing need for new approaches for accel
erating the processes associated with healing open wounds
such as but not limited to lacerations, diabetic ulcers, bed
Sores, and burns.
SUMMARY OF THE INVENTION

15

Briefly, therefore, the invention is directed to flexible dress
ing for wound care management comprising a three-dimen
sional compressible body of loose glass-based fibers; wherein
the fibers comprise one or more glass-formers selected from
the group consisting of POs, SiO, and BO; at least about

This invention relates to biocompatible dressings for care
of open wounds such as lacerations, diabetic ulcers, bed
Sores, and burns.
BACKGROUND OF THE INVENTION

25 wt % of the fibers have a diameter between about 200 nm.

As noted in U.S. Pat. No. 7,638,484, (i) inflammation; (ii)
fibroblast proliferation; (iii) blood vessel proliferation; (iv)
connective tissue synthesis; (V) epithelialization; and (vi)
wound contraction, are among the processes occurring during
healing of open cutaneous injuries. Various factors including
malnutrition, infection, and pharmacological agents can
affect the healing process.
U.S. Pat. No. 7,605,298 discloses a wound covering con
taining Ag, Cu, and/or Zn as an antimicrobially active Sub
stance bonded to the surface of a matrix. The covering
includes a first layer formed by an absorbent matrix and an
antimicrobially active Substance, the Substance being present
chemically or physically bonded to one surface of the matrix.
The Surface of the matrix including the Substance is coated
with a hydrophilic polymer. The matrix contains fibers and
can consist of a nonwoven material, of gauze, of a foam

and about 4000 nm, and a length:width aspect ratio of at least
about 10.
25

The invention is also directed to rigid dressing for wound
care management comprising a three-dimensional body of
bonded glass-based fibers; wherein the fibers comprise one or
more glass-formers selected from the group consisting of
POs, SiO, and BO; and at least about 25 wt % of the fibers

30

have a diameter between about 200 nm and about 4000 nm,

35

F. Fe, Mn, Mo, Ni, Sr., and Zn in a concentration between

material, or of another soft absorbent material. A foam mate

rial is stated to have the advantage that it can bind material
discharging from the wound and thereby can be kept remote
from the wound, so that it does not interfere with the healing
process. The matrix can contain at least one fiber or beformed

40

from at least one fiber.

U.S. Pat. No. 7,517,536 discloses a wound dressing com
prising a flexible base layer and an antimicrobial material,
wherein the antimicrobial material comprises an activated

about 0.05 and 10 wt % per trace element chemically dis
solved in the biocompatible material.
The invention is further directed to a biocompatible oint
ment or cream for wound care management comprising an
ointment-based carrier, glass-based particles of a biocompat
ible material intermixed in the ointment-based carrier,

45

carbon-carried noble metal. The activated carbon is selected

from among an activated carbon powder, an activated carbon
particle, and an activated carbon fiber. The noble metal is
selected from the group consisting of silver, gold, palladium,
platinum, copper, and zinc.
U.S. Pat. No. 7,495,146 discloses a wound dressing
employing silver compounds and copper compounds in par
ticles suspended in a fluid soluble material to establish elec
trochemical potential adjacent a healing wound.
U.S. Pat. No. 5,977,428 discloses an absorbent dressing
comprising a copper-containing compound or complex as a
micronutrient and a plurality of absorbent dried hydrogel
particles sealed within a porous container, wherein the porous
container is non-adherent to the wound. The absorbent hydro
gel particles, after absorbing the exudate, remain sealed
within the porous container.
U.S. Pat. No. 7,166,549 discloses grinding silicate glasses
ribbons into antimicrobial, anti-inflammatory, wound-heal
ing glass powders which may be added as a foodstuff Supple
ment, in cosmetic production, antiperspirant production, in

and a length:width aspect ratio of at least about 10.
In another aspect, the invention is directed to a dressing for
wound care management comprising a three-dimensional
compressible body of glass-based biocompatible material
comprising one or more glass-formers selected from the
group consisting of POs, SiO, and BO; and one or more
trace elements selected from the group consisting of Ag, Cu,

50
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wherein the glass-based particles comprise a glass-former
selected from the group consisting of POs, SiO, B.O.; and
one or more trace elements selected from the group consisting
of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn in a concentration
between about 0.05 and 10 wt % per trace element chemically
dissolved in the biocompatible material.
The invention is also directed to a biocompatible surgical
glue for closing a wound, wherein the glue comprises an
adhesive; glass-based particles of a biocompatible material
intermixed in the adhesive, wherein the glass-based particles
comprise a glass-former selected from the group consisting of
POs, SiO, BO; and one or more trace elements selected
from the group consisting of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr.
and Znina concentration between about 0.05 and 10 wt % per
trace element chemically dissolved in the biocompatible
material.

In a further embodiment the invention is a Surgical Suture
for closing a wound wherein the Suture comprises glass-based
fibers of a biocompatible material comprising a glass-former
selected from the group consisting of POs, SiO, B.O.; and
one or more trace elements selected from the group consisting
of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn in a concentration
between about 0.05 and 10 wt % per trace element chemically

US 8,535,710 B2
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dissolved in the biocompatible material; wherein the suture
comprises an external polymeric coating.
In another aspect the invention is directed to a method for
treating a wound comprising applying the dressings or oint
ment or cream to the wound, or applying the glue to close the

5

4
of the fibers, size of the dressing, and other factors. For
example, in most embodiments, there are hundreds or even
thousands offibers, such as typically at least about 10, at least
about 50, or at least about 200 fibers. The upper limit on the
number offibers is dictated by the size of the dressing, and for

wound.

some embodiments is less than about 50,000, while other

Other objects and features of the invention are in part
apparent and in part pointed out hereinafter.

embodiments contain more.

BRIEF DESCRIPTION OF THE FIGURES

10

FIG. 1 is a photograph of a three-dimensional compressible
body of loose glass-based fibers of the wound care dressing of
the invention.

FIG. 2 is a scanning electron microscope (SEM) image of
a body of loose glass-based fibers of the invention with glass
microspheres interspersed throughout the fibers.
FIG. 3 is a higher magnification SEM image of a body of
loose glass-based fibers of the dressing of the invention.
FIGS. 4 through 14 are photographs showing the healing
progression of wounds as described hereinbelow.
FIG. 15 is a graphical depiction of wound area as a function

15

ations.

The three-dimensional body of glass fibers as a whole has
a first state which is unstressed and relaxed when it is in an

uncompressed condition such as shown in FIG. 1. The body
also has a second state which is stressed when it is in a

of time as described hereinbelow.

FIGS. 16 through 20 are photographs of histological stain
ing (H&E) of a wound treated according to this invention.

25

DESCRIPTION OF PREFERRED
EMBODIMENTS

In accordance with this invention, biocompatible and bio
degradable glasses containing one or more glass-formers
selected from the group consisting of POs, SiO, and BO
are employed for wound care management. The glasses take
various forms, including a flexible three-dimensional com
pressible body of loose glass-based fibers to be held in place
in an open wound, or to be employed as a layer applied over
a wound. In another form, the glasses are in the form of
particles in an ointment or cream applied to a wound. In yet
other forms the glasses are employed as fibers formed into
Sutures for closing a wound, or as particles in a Surgical glue
for closing a wound.

30

35

40

45

50

55

60

transverse to the fiber's length. “Diameter as used herein
therefore refers not only to the diameter of a circular cross
section, but also to the largest transverse dimension of other,
The number of fibers in the assembly is not narrowly criti
cal to most embodiments, and varies depending on the length

The initial surface area of the compressible body varies
depending on morphology Such as whether it is all fibers, the
fiber dimensions, etc. Moreover, the surface area per unit
Volume changes upon compression, upon application to a
wound, and during biodegradation. Generally speaking, a
compressible body according to some embodiments of the
invention has a surface area/bulk body volume in the relaxed,
uncompressed state of the body of between about 1 and about

2000 cm, such as between about 50 and about 500 cm.

circular cross section, where cross section is the dimension

non-circular cross sections.

compressed condition, which generally occurs when the body
is shaped and applied to a wound. While the body as a whole
is unstressed in its uncompressed condition, the individual
fibers are to some extent stressed when they are bent. In the
relaxed state, the body has a porosity which is at least about
30% by volume, meaning that at least about 30 vol% of the
body is void space not occupied by glass material. For
example, in the relaxed state the body is between about 30 vol
% and about 90 vol% porosity, such as between about 40 vol
% and about 75 vol%. The body may be applied to a wound
in an uncompressed State; or it may be compressed so that the
porosity is between about 10 vol% and about 75 vol%, such
as between about 10 vol% and about 50 vol%. For example,
the body may have an uncompressed porosity of between
about 40 vol% and 75 vol% and a compressed porosity of
between about 10 vol% and about 30 vol%.

In a first embodiment of the invention which is a three

dimensional compressible body of loose glass-based fibers
such as depicted in FIG. 1, the body comprises fibers having
a diameter between about 200 nm (0.2 Lum (microns)) and
about 4000 nm (4 um). FIG.3 is an SEM image of such abody
showing various fiber diameters at higher magnification. For
example, in one embodiment the fibers have a diameter
between about 250 nm (0.25um) and about 3000 nm (3 um),
such as between about between about 300 nm (0.2 um) and
about 2000 nm (2 um). The especially small diameter of these
fibers renders them highly flexible so they form into the
compressible body withoutbreaking. They have a texture like
a cottonball In certain embodiments the body consists only of
fibers meeting these dimensions, while in other embodiments
the body includes fibers meeting these dimensional require
ments in addition to other glass morphologies, such as fibers
of other dimensions, microspheres, particles, ribbons, flakes
or the like. The fibers are generally circular in cross section,
but they may be flattish or oval or have other-shaped, non

As shown in FIG. 2, the body may also contain, in addition
to fine glass fibers, microspheres or beads having a diameter
of at least about 10 um, such as between about 10 um and
about 500 um, for example between about 20 Lum and about
300 lum. In addition to or instead of microspheres, these
components may be irregular or regular particles, ribbons,
flakes, hollow spheres, or other shapes. While microspheres
are preferred in some embodiments, the shape is not narrowly
critical in most embodiments, and is to a large extent dictated
more by the availability of materials than by other consider

65

In the embodiment shown in FIGS. 1 through 3 the fibers
are randomly oriented in the body. In alternative embodi
ments, the fibers may be woven, as may be dictated either by
the manner in which the body is formed, or may be dictated by
a particular application. For example, in one embodiment the
body is in the form of a woven layer which is applied over a
wound, similar in morphology to a woven cloth orgauze. The
layer may be wrapped around the wound. This layer may
constitute the entire dressing, or it may be a component of a
multi-component dressing, Such as a multilayer dressing.
Inasmuch as the layer may constitute the entire dressing, the
term “layer herein is not strictly limited to a layer which is
laid over or under another component of the dressing.
When in the form of a layer, the body is also suitable for
wrapping around or otherwise applying to an implant Such as
a hip implant or a bone repair implant. This assists in fixation
of the implant in the body. Moreover, the body of glass fibers
in this application is suitable for delivering trace elements to
the implant site by incorporating trace elements chemically
dissolved in the glass material, as described hereinbelow. In

US 8,535,710 B2
5
these applications where the glass body is a layer, it is flexible.
Randomly oriented as well as woven fibers may be employed

6
um, such as between about 3 and about 50 um. In the context
of the glue, ointment, and cream, the term "particles' includes

in these embodiments.

fibers.

The three-dimensional body has a length, width, and thick
ness. In irregularly shaped embodiments such as shown in
FIG. 1, these dimensions refer to the largest or maximum
dimensions in each of the X, y, and Z directions. For example,
the particular embodiment shown in FIG. 1 has a length of
about 75 mm (3 inches as shown by the ruler), a width of about
50 mm, and a thickness of about 5 to 25 mm. Generally
speaking, the dimensions of the body are dictated by the size
of the wounds for which it is applicable. The body therefore
typically has an uncompressed length and width of at least
about 10 mm, such as between about 10 mm and about 250

mm, for example between about 10 and about 150 mm.

5

10

15

between about 10 and about 50 mm, or between about 50 and

200 mm. The body typically has an uncompressed thickness
of at least about 2 mm, such as between about 2 and about 100

mm or between about 5 and 30 mm. The body may be manu
factured or Supplied to the end users or intermediaries in
much larger dimensions, and cut to size by the end users or
intermediaries.

In those embodiments where the body is in the form of a
layer, the thickness is generally much Smaller, for example

25

less than 10 mm, such as between about 1 mm and 10 mm. In
one embodiment it is between about 1 and about 3 mm thick.

The layer may be in the form of a square, for example having
a length and width between about 10 and about 300 mm, or in
the form of a rectangle having a width between about 10 and
about 75 mm and a length between about 50 and about 250
mm. The layer may also be in the form of a roll having a width
between about 10 and about 75 mm and a length greater than
25 mm. In some preferred embodiments where the body is a
layer, it has a length and a width which are between about 5
and about 30 times the thickness of the body.
In one embodiment the body is subjected to a bonding
operation which at least lightly bonds the fibers and converts
the body from a flexible body to a rigid body. This yields a
rigid dressing for wound care management comprising a
three-dimensional body of bonded glass-based fibers.
The invention in another aspect is a biocompatible oint
ment or cream for wound care management. This embodi
ment employs any ointment-based or cream-based carrier
which one skilled in the art determines is suitable for treat

ment of the particular wound. Glass-based particles of a bio
compatible material are intermixed in the ointment-based or
cream-based carrier. The glass-based particles comprise a
glass-former selected from the group consisting of POs,
SiO, BOs. The glass-based particles further comprise one
or more trace elements selected from the group consisting of
Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. and Zn in a concentration
between about 0.05 and 10 wt % per trace element chemically
dissolved in the biocompatible material.
The invention in another embodiment is a biocompatible
Surgical glue for closing a wound. The glue comprises an

In those instances when the one or more trace elements are
30

35

40

45

tration of at least about 0.05 wt %, or at least about 0.1 wt %.
In most instances, the concentration is less than 10 wt %, or
less than 5 wt %, such as between about 0.05 and about 5 wt

%, for example between about 0.1 and about 2.5 wt % (per
element). Where the biocompatible glass material is borate
based orphosphate-based, the trace element concentration is
less than 5 wt %, and it may be higher and up to 10 wt % where
the biocompatible material is silicate-based. The trace ele
ments are selected from the group consisting of Ag, Cu, F, Fe,
Mn, Mo, Ni, Sr. and Zn. In certain preferred embodiments the
trace element is one or more selected from the group consist
ing of Ag, Cu, Fe, Sr. and Zn. More than one of these trace
elements can be employed in a single composition. Also,
certain of these elements may be present in greater amounts in
that they are not being used as trace elements in accordance
with this invention. For example, a glass which contains 0.4
wt % Cu and 15 wt % Sr contains Cu as a trace element in

accordance with this invention; and it contains Sr, but not as
a trace element in accordance with this invention. Such a
50

55

60

material would indeed satisfy the requirement herein for a
trace element from the group Ag, Cu, F, Fe, Mn, Mo, Ni, Sr.
and Zn in a concentration between about 0.05 and 10 wt % by
virtue of the materials Cu content, regardless of its unduali
fying Sr content.
Where Cu is desired, the source of Cu to the glass may be
a copper oxide Such as CuO or CuO or other copper com
pounds such as copper nitrate or copper Sulfate, for example.
In one embodiment, Cu is incorporated in a concentration of
between about 0.05 and about 5 wt % (about 0.06-6 wt %
CuO; about 0.055-5.5 wt %CuO), such as between about 0.1
and about 2.5 wt % (about 0.12-3 wt %CuO; about 0.11-3 wit
% Cu.O). There are preferred embodiments employing from
about 1 wt % to about 2 wt % Cu, as provided by between
about 1.2 wt % and about 2.4 wt % Cu.O.

Ni, Sr., and Zn in a concentration between about 0.05 and 10

wt % per trace element chemically dissolved in the biocom
patible material. The particle size for glass-based particles in
the ointment, cream, or glue is between about 1 and about 300

Ni, Sr., and Zn in a concentration between about 0.05 and 10

wt % per trace element chemically dissolved in the biocom
patible material. The suture preferably has an external poly
meric coating.
In connection with each of the foregoing embodiments, a
trace element such as Ag, Cu, F, Fe, Mn, Mo, Ni, Sr., and Zn,
and in some particularly preferred embodiments, Ag, Cu, Sr.
Zn, and/or Fe, is preferably incorporated into the glass. Silver
has infection-fighting properties. These other elements have
an effect on endothelial cell migration which can be useful for
blood vessel formation and have importance for tissue regen
eration. In this way, these trace elements promote angiogen
esis, which is a critical function in promoting tissue growth,
Such as in wound healing. This is in distinction from promot
ing osteoconductivity, which refers to providing bone growth
factors to a site to promote bone growth. Angiogenesis, which
involves increasing vascularity, i.e., vessel growth, is distinct
from osteoconductivity.
employed, they are incorporated into the glass in a concen

adhesive which one skilled in the art determines is suitable for

treatment of the particular wound. The glue also contains
particles of a biocompatible material intermixed in the adhe
sive, wherein the glass-based particles comprise a glass
former selected from the group consisting of POs, SiO,
BO. The particles also contain one or more trace elements
selected from the group consisting of Ag, Cu, F, Fe, Mn, Mo,

Another embodiment is a Surgical Suture for closing a
wound wherein the Suture comprises glass-based fibers of a
biocompatible material comprising a glass-former selected
from the group consisting of POs, SiO, B.O. The glass
based fibers further comprise one or more trace elements
selected from the group consisting of Ag, Cu, F, Fe, Mn, Mo,

65

Where Sr is desired, the source of Sr to the glass may be an
oxide such as SrO or other Sr compounds such as SrCO, for
example. In one embodiment, Sr is incorporated in a concen
tration of between about 0.05 and about 5 wt % (about 0.06 to
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5.90 wt % SrO), such as between about 0.1 and about 2.5 wt
% (about 0.12 to 2.95 wt % SrO). There are preferred embodi
ments employing from about 1 wt % to about 2 wt % Sr, as
provided by between about 1.18 wt % and about 2.36 wt %
SrO.

5

8
200 and 300 grams. In accord with this measure, the testing is
performed on rats with a standard deviation of 25% (relative)
of the biocompatible material and a population size of 10. In
other words, when 10 of bodies, ointments, creams, glues, or
Sutures are applied to rat wounds, on average at least 20 wt %

Where Zn is desired, the source of Zn to the glass may be of the trace element concentration is released within two
weeks; and in at least 68% of rats at least 15 wt % of the trace
an oxide such as ZnO or other Zn compounds such as Zn
(PO4)2-XH2O, for example. In one embodiment, Zn is incor element concentration is released; and in at least 90% of rats
porated into the glass in a concentration of between about at least 10 wt % of the trace element concentration is released.
0.05 and about 5 wt % (about 0.06 to 6.0 wt % ZnO), such as 10 On the other hand, the glass in most embodiments does not
between about 0.1 and about 2.5 wt % (about 0.12 to 3.0 wt % biodegrade so quickly upon application to the host that it fails
ZnO). There are preferred embodiments employing from to provide trace elements over a long enough period to
about 1 wt % to about 2 wt % Zn, as provided by between adequately promote angiogenesis. For example, at least 30 wit
about 1.20 wt % and about 2.40 wt % ZnO.

% of the material remains for at least two weeks and does not

Where Fe is desired, the source of Fe to the glass may be an 15 biodegrade within two weeks. That is, the concentrations of
oxide such as FeC), Fe-O, FeO, or other Fe compounds glass formers are balanced such that at least about 30 wt % of
such as FeSO-7H2O, for example. In one embodiment, Fe is the biocompatible glass material remains in the bodies, oint
incorporated into the glass in a concentration of between ments, creams, glues, or Sutures for at least two weeks after
about 0.05 and about 5 wt % (about 0.06 to 6.45 wt % Fe0), application to a Fisher 344 rathaving an age between 9 and 11
such as between about 0.1 and about 2.5 wt % (about 0.13 to 20 weeks and a weight between 200 and 300 grams. In accord
3.23 wt % FeC). There are preferred embodiments employing with this measure, the testing is performed on rats with a
from about 1 wt % to about 2 wt % Fe, as provided by between standard deviation of 25% (relative) of the glass and a popu
about 1.29 wt % and about 2.58 wt % FeC).

lation size of 10. In other words, when 10 of these bodies,

Where Ag is desired, the Source of Ag to the glass may be ointments, creams, glues, or Sutures are applied to rat wounds,
AgNO or AgPOs, for example. In one embodiment, Ag is 25 on average at least 30 wt % of the glass does not biodegrade
incorporated in a concentration of between about 0.05 and within two weeks; and in at least 68% of rats at least 22.5 wt
% of the glass does not biodegrade within two weeks; and in
about 5 wt %, such as between about 0.1 and about 2.5 wt %.
The glass formers in certain embodiments of the invention at least 90% of rats at least 15 wt % of the glass does not
are concentration balanced to impart the desired biodegrad biodegrade within two weeks.
ability. For example, in one embodiment, the concentrations 30 Moreover, in these embodiments, at least 30 wt % of the
of the glass formers borate, silicate, and phosphate are bal trace element concentration remains in the bodies, ointments,
anced to 52.95 wt %, 0 wt %, and 4.0 wt %, respectively, with creams, glues, or sutures for at least two weeks. That is, the
respect to themselves and with respect to the other compo concentrations of glass formers are balanced such that at least
nents in the material NaO, CaO, and KO. Balancing in this about 30 wt % of the trace element remains for at least two
regard encompasses balancing the concentration of one glass 35 weeks after application to a Fisher 344 rat having an age
former with other components, such as with those glasses between 9 and 11 weeks and a weight between 200 and 300
which containborate and other components, but no phosphate grams. In accord with this measure, the testing is performed
or silicate.
on rats with a standard deviation of 25% (relative) of the
In many preferred embodiments, the concentrations of biocompatible body material and a population size of 10. In
glass formers are balanced such that at least about 20 wt % of 40 other words, when 10 of these bodies, ointments, creams,
the glass biodegrades within two weeks of application to a glues, or Sutures are applied to rat wounds, on average at least
wound. For example, the concentrations of glass formers are 50 wt % of the trace element concentration remains for at least
balanced such that at least about 20 wt % of the glass biode two weeks; and in at least 68% of rats at least 22.5 wt % of the
grades within two weeks of application to a Surface wound of trace element concentration remains in the bodies, ointments,
a Fisher 344 rathaving an age between 9 and 11 weeks and a 45 creams, glues, or Sutures for at least two weeks; and in at least
weight between 200 and 300 grams. In accord with this mea 90% of rats at least 15 wt % of the trace element concentration
Sure, the testing is performed on rats with a standard deviation remains for at least two weeks.
of 25% (relative) of the biocompatible material and a popu
In one embodiment of the invention the glass releases the
lation size of 10. In other words, when 10 of these bodies,
trace element at particular rate of release of trace element, per
ointments, creams, glues, or Sutures are applied to rat wounds, 50 gram of glass, per day in a mammalian host. The release rate
on average at least 20 wt % of the glass biodegrades within can in effect be “dialed in” by determining the desired amount
two weeks; and in at least 68% of rats at least 15 wt % of the

of trace element to be released within the host, and then

glass biodegrades; and in at least 90% of rats at least 10 wt % selecting a biocompatible composition or combination of
of the glass degrades. Application for this and the following compositions to achieve this rate. As noted above, the glass
standards is according to the protocol described below in 55 formers are concentration balanced to impart the desired bio
Example 1. Biodegrading in most instances manifests itself as degradability. In a related aspect, the Surface area per unit
weight loss, but can also manifest itself as another reaction of Volume can be controlled to control release rate, as greater
the material.
Surface area increases reactivity and therefore release rate.
Similarly, in another aspect, the concentrations of glass One skilled in the art appreciates that the rate of biodegrada
formers are balanced such that at least about 20 wt % of the 60 tion of the glass is different from host to host, from glass to
trace element concentration in the bodies, ointments, creams,
glass, from trace element to trace element, and otherwise
glues, or sutures is released into the host within two weeks of depends on a number of factors. For example, a more physi
application to its mammalian host. For example, the concen cally active host with a faster average heart rate may encour
trations of glass formers are balanced such that at least about age biodegradation and therefore trace element release at a
20 wt % of the trace element concentration is released into the 65 faster rate. In one embodiment, the composition has a trace
host within two weeks of application to a Fisher 344 rat element release (Cu) rate of between about 0.5 and about 100
having an age between 9 and 11 weeks and a weight between E-7 moles of trace element, per gram of glass, per day; for
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example, between about 1 and about 25 E-7 moles of trace
element, per gram of glass, per day; Such as between about 1
and about 20 E-7 moles of trace element, per gram of glass,
per day, or between about 3 and about 12 E-7 moles of trace
element, per gram of glass, per day.

As noted above, the glass inventive bodies and other forms
biodegrades or reacts when in contact with physiological
fluids. However, in comparison to articles characterized as
“water soluble' which dissolve relatively rapidly (over a
period of, e.g., 24 hours or less) in aqueous solutions, the
biocompatible materials of the invention are not readily
soluble in water or aqueous liquids such as physiological
liquids, that is, they slowly react with aqueous liquids over a
periods of several days to weeks for the fine fibers and gen
erally weeks to months for the microspheres and larger diam
eter particles. As understood in the art, materials which are
“water soluble' are subject to relatively rapid solubility; and
materials which are “water insoluble' are either entirely
insoluble in water, or are at least only dissolvable with diffi
culty. Generally speaking the glass employed in the embodi

-continued
SiO,
Al2O3

5

O to 4
O to 10
cumulative.

The concentrations of KO and MgO in certain of these

embodiments are each from about 1 to about 25 wt.%. In most
10

15

embodiments, the one or more of LiO, NaO, KO, and
Rb2O is present in a cumulative concentration between about
1 and about 50 wt %, such as between about 5 and about 20 wt
%; and the one or more of MgO, SrO. BaO, and CaO is
present in a cumulative concentration between about 1 and
about 50 wt %, such as between about 5 and about 40 wt %.
Where Cu is an optionally included trace element, this com
position further contains 0.05 to 5; or 0.01 to 2.5 wt % Cu; as
CuO, CuO, or other Cu compound. The transition metal
elements are those elements where the d-band contains less

than its maximum number of ten electrons per atom, and
includes, among others, Co and Ni. In fact, certain of the trace

ments of this invention are not water insoluble and are not

water soluble under this characterization; rather, they are of
intermediate water solubility.
The glass material of the bodies, ointments, creams, glues,
or sutures is biocompatible in that it is not toxic or otherwise
harmful to its host’s living tissue. Some of the preferred
compositions (Ca-free) of the invention are also not bioactive,
in the sense that hydroxyapatite does not form. That is, they
lack bioactivity, where bioactivity refers to a materials
capacity in phosphorus-containing mammalian fluids to fos

O to 18
O to 3

F
transition metal elements

elements used in accordance with this invention Such as Zn
and Fe are transition metals. So in formulations where the
trace element concentration of these trace elements is stated
25

to be in aparticular range Such as between about 0.1 and about
2.5 wt %, of course the trace element concentration is in that

range regardless of the fact that transition elements may be
among the trace elements, and if Zn and Fe are present in an
amount greater than 2.5 wt %, they are not trace elements.
A few exemplary glass materials useful in the invention are
as follows:
TABLE 1.

Trace-Element-Containing Borate Biocompatible Glasses (wt %
Glass B.O.

Na-O

CaO

K-O

MgO POs CuO SrO ZnO FeO.

S.99
S.99
S.98.
S.94
S.88
S.86
S.80
5.76

19.98
19.96
19.92
19.8O
19.6O
19.52
19.32
19.2O

11.99
11.98
11.9S
11.88
11.76
11.71
11.59
1152

SOO
4.99
4.98
4.95
4.90
4.88
4.83
4.80

S2.95
52.89
52.79
52.47
S1.94
S1.73
S120
SO.88

4.OO
3.99
3.98
3.96
3.92
3.90
3.86
3.84

0.10
0.2O
0.40
1.00
2.00
O.40
0.40
040

2.00
2.OO
2.OO

100
100

O4O

45

ter growth of a calcium phosphate layer or convert to bone
precursor calcium phosphate compounds which, in turn, pro
motes bone bonding to the material.
In one embodiment the glass employed is aborate-based
glass material containing the following, approximately, with 50
all percentages herein being by weight, unless stated other
W1S

55

B2O3
Na2O
Li2O
KO
Rb2O

40 to 8O
O to 25
O to 25
O to 25
O to 25

CaO

O to 40

MgO

O to 25

SO
BaO

O to 40
O to SO

Li2O + NaO + K2O + Rb2O

In most embodiments the compressible body or glass par
ticles consist only or essentially of components meeting these
compositional requirements or other narrower descriptions
herein. But generally speaking, for Some embodiments other
materials not meeting these descriptions may be incorpo
rated.

Additional borate-based materials within this description,
into which Ag, Cu or other stated trace element may be
incorporated according to this invention, contain, by weight
%, the following, keeping in mind that one or more of the
other trace elements may be included in addition to Cu in
analogous concentrations, or instead of Cu:
TABLE 2

60

Wt. 90 Composition of Additional Borate Glasses

O to SO
cumulative

MgO + SrO + BaO + CaO
POs

O to SO
cumulative
O to 10

65

A
B
C

B.O.

Na-O

52.5
70.3
63.7

6.O

K-O LiO CaO BaO MgO POs CuO
12.O
10.3

19.0

2O.O
19.3
17.2

S.O

4.0

O.S
O.1
O.1
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TABLE 2-continued
Wt. 90 Composition of Additional Borate Glasses
D
E
F
G
H
I
J

B.O.

Na2O

K-O Li2O CaO BaO MgO POs CuO

490
78.4
69.9
78.6
78.6
75.9
58.6

14.6

36.0
11.S
1OO
11.3
11.3
11.0
8.0

10.0
100

10.O
1O.O
1O.O
13.0
33.0

0.4
O.1
O.1
O.1
O.1
O.1
0.4

It can therefore be appreciated that in addition to the Cu,
and/or in addition to Ag, Cu, F, Fe, Mn, Mo, Sr. and/or Zn, the
borate-based biocompatible glass materials include 40 to 80
wt % BO or 50 to 80 wt % BO, or even the narrower BO
ranges described herein, in combination with 1 to 25 wt %
NaO, 1 to 25% KO, 1 to 40 wt % CaO, 1 to 25 wt % MgO,
and 1 to 10 wt % POs. Or the component materials may
contain 40 to 80 wt % BO, 1 to 25 wt % LiO, and 1 to 40
wt % CaO. Or they may contain 40 to 80 wt % BO, 1 to 25
wt % NaO, and 1 to 40 wt % CaO. Or they may contain 40 to
80 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaC). Or
they may contain 40 to 80 wt % BO, 1 to 25 wt % LiO, and
1 to 25 wt % MgO. Or they may contain 40 to 80 wt % BO,
1 to 25 wt % LiO, and 1 to 40 wt % BaO. While the biocom
patible materials hereinabove and hereinbelow are described
as containing various oxides by weight%, those skilled in the
art understand that in the final glass or glass/crystalline com
position, the oxide compounds are dissociated, and the spe
cific oxides, e.g., B.O., SiO, POs, etc. are not separately
identifiable or even necessarily separately present. Nonethe
less, it is conventional in the art to refer to the final composi
tion as containing a given 9% of the individual oxides, so that
is done here. So from this perspective, the compositions
herein are on an equivalent basis.
The biocompatible glass employed in the invention con
taining the trace element in certain preferred versions are
borate-based in that they contain between about 40 and about
80 wt % BO, such as between about 50 and about 80 wt %
B.O. Borate-based materials have several important advan
tages for biological use Such as their ease of preparation,
ability to be made into glass particulates, microspheres or
fibers at relatively low temperatures without crystallization,
and, particularly, their biocompatibility. The borate-based
materials disclosed herein, compared to silicate-based mate
rials, have significantly faster reaction rates, lower melting
temperatures, resistance to crystallization, and in certain
instances the absence of silica, which only slowly degrades in
the body. So while certain embodiments employ up to about
18 wt % SiO in many other preferred embodiments herein,
the materials are silicate-free, containing less than 0.1 wt %
silicate or even no silicate. Borate glass fibers often form
hollow fibers upon reaction in-vivo, while silicate glasses do
not; and they facilitate angiogenesis in-vivo. The borate mate
rials described herein also release boron in-vivo as they react
with the body fluids.
There is one embodiment which has specific preference in
certain applications and wherein the concentration of Ca (el
emental or in CaO or other compounds) in the glass is con
trolled to less than about 5 wt %. Certain preferred embodi
ments strictly control the Ca concentration to less than about

5
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15

25

30
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B2O3
Na2O
Li2O
KO
Rb,O
MgO

40 to 80
O to 25
O to 25
O to 25
O to 25
O to 25

SO
BaO

O to 40
O to 25

LiO + NaO + K-O + Rb-O

POs
SiO2
Al2O3
40

transition metal elements

45

O to SO
cumulative

MgO + SrO + BaO

O to SO
cumulative
O to 10
O to 18
O to 3
O to 4
O to 10
cumulative.

In addition, the material optionally contains Cu in a concen
tration of 0.05 to 5; or 0.01 to 2.5 wt %, as CuO, CuO, or
other Cu compound, and/or other trace element. Certain of
these embodiments contain low levels of Ca, as described

50

above; while others are substantially Ca-free and contain
essentially no or less than 0.1 wt % Ca.
In one preferred embodiment, the glass contains between
about 50 and about 80 wt % B.O.; between about 5 and about
20 wt % alkali oxide component selected from the group
consisting of LiO, Na2O, K2O, Rb2O, and combinations
thereof, and between about 5 and about 40% alkaline earth

55

60

0.5 wt %, such as to less than 0.2 wt %, and even to less than

0.1 wt %. The advantage in this embodiment to strictly con
trolling Ca concentration is the avoidance of the formation of
calcium phosphate compounds, apatite type compounds, and

12
related amorphous calcium phosphate (ACP) upon exposure
to physiological phosphorus-containing fluids. Such apatite
compounds includehydroxyapatite Cas (PO4)(OH), fluoroa
patite Cas (PO).F. amorphous calcium phosphate (ACP), and
other calcium-containing compounds. Thus, in certain appli
cations it is advantageous to avoid the formation of Ca-apatite
compounds because they have a relatively lower radiopacity
than do, for example, analogous Sr or Ba compounds. In
certain situations it is advantageous to avoid Ca-apatite com
pounds in order to form compounds which degrade more
rapidly, or perhaps even more slowly. It can also be advanta
geous to avoid Ca for purposes of controlling melt character
istics, such as viscosity, melting temperature, and/or crystal
lization tendency. The Ca-free compositions lack bioactivity,
where bioactivity refers to a materials capacity in phospho
rus-containing mammalian fluids to foster growth of a cal
cium phosphate layer or convert to bone-precursor calcium
phosphate compounds.
The biocompatible Ca-free material employed for certain
embodiments preferably contains between about 40 and
about 90 wt % BO with the remainder being selected from
alkali oxides and alkaline earth oxides, and other optional
constituents listed below. For example, this material contains,
by weight%:

65

component selected from the group consisting of MgO, SrO.
BaO, and combinations thereof. Optional components
include POs, SiO, Al2O, F, and transition metal elements.
Lanthanides are specifically and strictly excluded from cer
tain preferred embodiments. In some embodiments the bio
compatible material consists essentially of between about 50
and about 80 wt % B.O.; between about 5 and about 20 wt %
alkali oxide component selected from the group consisting of
LiO, NaO, KO, Rb O, and combinations thereof; between
about 5 and about 40 wt % alkaline earth component selected
from the group consisting of MgO, SrO, BaO, and combina
tions thereof, and between about 0.05 and 5 wt % Cu, as CuO,

Cu2O, or other Cu compound
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Exemplary borate-based Ca-free materials, into which Cu
may be incorporated according to this invention, contain, by
weight%, the following; keeping in mind that one or more of
the other trace elements may be included in addition to Cu in
analogous concentrations, or instead of Cu:

14
from about 1 to about 50 wt %, such as from about 5 to about
25 wt %, and even from about 8 to about 20 wt %; and even
5

TABLE 3

Wt. 90 Composition of Ca-Free Borate Glasses
I
II
III
IV
V
VI
VII

BO

NaO

49.O
78.7
78.7
75.8
58.7
4S.O
69.7

14.6

Li2O

MgO

11.1
11.1
11.0
8.0
6.6
1O.O

1O.O

1O.O

BaO

CuO

36.1

O.3
O.2
O.2
O.2
O.3
0.4
O.3

1O.O
13.0
33.0
48.0
1O.O

10
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as to less than 0.2 wt % or less than 0.1 wt % to avoid the

In certain embodiments of the invention, the glass is
selected to include at least two of the alkali oxides LiO,
NaO, KO, and/or RbO in a cumulative concentration of
between about 5 and about 25 wt %, such as between about 8

and 20 wt %. It has been discovered to be advantageous to
include two or more such alkali compounds in order to reduce
the tendency for crystallization, which ultimately improves
the workability and manufacturability of the glasses. Using
more than one type of alkali (i.e., mixed alkali) can reduce the
cost of a glass, modify its reaction rate with body fluids, and
provide additional elements beneficial to tissue growth and
regeneration.

25

30

A further feature of certain embodiments is that the cumu
lative concentration of the alkaline earth oxides from the

group consisting of MgO, SrO. BaO, CaO, and combinations
thereof is in the range of 1 to about 50 wt %, such as in the
range of 1 to 30 wt %, or even about 8 to 25 wt %. Certain of

35

these embodiments contain two or more Such alkaline earth

oxides in a range of 1 to 45 wt % cumulatively, Such as in the
range of 5 to 25 wt %. If SrO is present in a concentration
which yields a Sr concentration above 10 wt %, it does not
qualify as a trace element in accordance with this description.

formation of Ca compounds, in the manner discussed above.
Alternatively, there are embodiments containing two or more
alkali oxides which also contain CaO in an amount up to
about 40 wt % to facilitate the formation of hydroxyapatite,
other calcium phosphate compounds, or amorphous calcium
phosphate.
Some exemplary materials of the invention contain,
approximately, 40 to 80 wt % BO, 0.05 to 5% CuO, and
NaO, K2O, MgO, and POs. More specific examples contain
or even consist essentially of 40 to 90 wt % BO, 0.1 to 5%
CuO, 1 to 25 wt % NaO, 1 to 25 wt % K2O, 1 to 25 wt %
MgO, and 1 to 10 wt % P.O.
The invention in other embodiments employs glasses
formed from a phosphate-based or silicate-based material
which is at least partially dissolvable in mammalian bodily
fluids, and Cu or other trace element is optionally incorpo
rated into the biocompatible material in a concentration as
described above. In these embodiments, POs and/or SiO, are
glass formers and constitute about 20 to about 65 wt % P.O.
or about 20 to about 60 wt % SiO. These materials also
contain an alkali metal oxide component of for example, one
or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture
thereof in a concentration of about 8 wt % to about 55 wt %,

40

These embodiments into which Cu and/or other trace ele

ment may be incorporated and which employ mixed alkali
oxide contents contain BOs from about 40 to about 80 wt %.
Certain of these embodiments consist essentially of BO
from about 40 to about 80 wt %, mixed alkali oxides selected

optionally two or more such oxides cumulatively in this
range. They also optionally employ alkaline earth oxides
from group consisting of MgO, SrO. BaO, CaO, and combi
nations thereof in the range of about 1 to about 50 wt %, such
as in the range of 1 to 30 wt %, or even about 8 to 25 wt %, and
even two or more such oxides cumulatively in this range.
Certain of these embodiments consist essentially of these
components, such as compositions II, III, IV, and VII in Table
3; while other embodiments optionally include one or more of
POs, SiO, Al2O, F, and transition metal elements.
In the foregoing described mixed-alkali and high-borate
embodiments, the Ca concentration may be strictly controlled
to less than about 5 wt %, including to less than 0.5 wt %, such

45

from the group consisting of LiO, Na2O, K2O, and Rb2O,
and one of MgO, SrO, BaO, or CaO, plus the Cu or other trace
element compound. Other embodiments consist essentially
of BO, from about 40 to about 80 wt %, two or more alkali
oxides selected from the group consisting of Li2O, NaO.
KO, and RbC), and two or more alkaline earth oxides from
the group consisting of MgO, SrO. BaO, and CaO, plus the Cu
or other trace element compound. For example, composition
A in Table 2 consists essentially of B.O. from about 40 to

50

about 80 wt %, two or more mixed alkali oxides selected from

55

such as about 10 to about 52 wt %. Many of these phosphate
and silicate-based glasses also contain a calcium component,
one of CaO, CaF, or mixtures thereof. For example, many of
these glasses contain from about 5 to about 40 wt % of CaO or
CaF, or mixtures thereof, such as about 10 to about 30 wt %
of CaO or CaF, or mixtures thereof, or about 10 to about 15
wt % of CaO or CaF, or mixtures thereof. Accordingly, one
of these embodiments contains about 20 to about 65 wt %

POs, and one or more of LiO, NaO, K2O, Rb2O, CSO, or

a mixture thereof in a concentration of about 8 wt % to about

55 wt %, and a calcium componentina concentration of about
5 to about 40 wt % of CaO or CaF, and optionally Cu in a
concentration of about 0.05 to about 5 wt %, such as between
about 0.1 and about 2.5%. Another embodiment contains

about 20 to about 65 wt % P.O.s, and one or more of LiO,
NaO, K2O, Rb2O, Cs-O, or a mixture thereof in a concen

the group consisting of LiO, NaO, KO, and Rb2O in a

tration of about 10 wt % to about 52 wt %, a calcium com

cumulative wt % between 5 and 25%, and two or more from

ponent of CaO or CaFor mixtures thereof in a concentration
of about 5 wt % to about 40 wt % of CaO or CaF2 or mixtures

among MgO, SrO. BaO, and CaO in a cumulative wt %
between 8 and 25%. Other embodiments optionally include
one or more of POs, SiO, Al-O. F. and transition metal

60

thereof, and Cu or other trace element in a concentration of
about 0.05 to about 5 wt %, such as between about 0.1 and

elements.

about 2.5%. Another embodiment contains about 20 to about

The invention includes using fibers or particles from bio
compatible glass materials with an especially high BO com
position, namely, from about 60 to about 82 wt %, preferably
from about 70 to about 80 wt %. These embodiments employ
an alkali oxide selected from the group consisting of LiO,
NaO, KO, RbC), and combinations thereof cumulatively

65 wt % POs, and one or more of LiO, NaO, K2O, Rb2O,
Cs-O, or a mixture thereof in a concentration of about 8 wt %
to about 55 wt %, a calcium component of CaO or CaF or
65

mixtures thereof in a concentration of about 10 to about 30 wt

% of CaO or CaFor mixtures thereof, and Cu or other trace
elementina concentration of about 0.05 to about 5 wt %, such
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manufacturability of the glasses, which can be important to
embodiments contains about 20 to about 60 wt % SiO, and making fibers. Using more than one type of alkali (i.e., mixed
one or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture alkali) can reduce the cost of a glass, modify its reaction rate
thereof in a concentration of about 8 wt % to about 55 wt %,
with body fluids, and provide additional elements beneficial
a calcium component of CaO in a concentration of about 5 to 5 to tissue growth and regeneration.
A further feature of these phosphate-based embodiments is
about 40 wt % of CaO or CaF2, and Cu or other trace element
as between about 0.1 and about 2.5%. Another of these

that the cumulative concentration of the alkaline earth oxides

in a concentration of about 0.05 to about 5 wt %, such as

from the group consisting of MgO, SrO. BaO, CaO, and
contains about 20 to about 60 wt % SiO, and one or more of combinations thereof is in the range of 1 to about 50 wt %,
LiO, NaO, KO, Rb2O, CSO, or a mixture thereof in a 10 such as in the range of 1 to 30 wt %, or even about 8 to 25 wt

between about 0.1 and about 2.5 wt %. Another embodiment

%. Certain of these embodiments contain two or more such

concentration of about 10 wt % to about 52 wt %, a calcium

alkaline earth oxides in a range of 1 to 45 wt % cumulatively,
such as in the range of 5 to 25 wt %.
There is also an option with this invention of employing
a concentration of about 0.05 to about 5 wt %, such as 15 distinct component compositions to strategically impart cer
between about 0.1 and about 2.5 wt %. Another embodiment
tain properties. For example, the compressible body, oint
contains about 20 to about 60 wt % SiO, and one or more of ment, cream, glue, or Suture in Some embodiments employs
10 to 90 wt % of components having one composition
LiO, NaO, KO, Rb2O, CSO, or a mixture thereof in a
concentration of about 8 wt % to about 55 wt %, a calcium
selected from the above, and 10 to 90 wt % of components of
component of CaO or CaF2 or mixtures thereof in a concen- 20 a different composition. Or even more than two such types of
tration of about 10 to about 30 wt % of CaO or CaF, or components may be employed. That is, the material may
mixtures thereof, and optionally Cuor other trace element in contain at least 10 wt % of components comprising a first
component material within the contemplated compositions
a concentration of about 0.05 to about 5 wt %, such as
between about 0.1 and about 2.5 wt %. In certain of these
and at least 10 wt % of components comprising a second
embodiments, CaF2 is strictly avoided and the calcium com- 25 component material, wherein the first and second component
ponent is CaO.
materials have compositions distinct from each other. And it
Examples of silicate-based glasses containing Cu and other is contemplated that only the first component material may
trace elements useful in this invention are as follows:
contain Cu and/or other trace element. This permits the selec
component of CaO or CaF2 or mixtures thereof in a concen
tration of about 5 wt % to about 40 wt % of CaO or CaFor
mixtures thereof, and optionally Cuor other trace element in

TABLE 4

Weight Percent Composition of Silicate-Based Biocompatible Glasses (wt %
Glass SiO, Na2O POs CaO CuO Fe0 CaF2 BO, ZnO MnO MgO KO
44.6
44.1
43.7
43.2
42.8
44.O
SO.O

24.3
24.O
23.8
23.5
23.3
25.O
6.O

5.9
5.9
S.8
5.8
5.7
6.O

24.3
24.O
23.8
23:S
233
20.0
19.0

1.0
2.0
3.0
4.0
SO
O2
O2

O.2
O.2

1.O
1.O

2.2
3.0

O6
1.O

O.2
O.2

Examples of phosphate-based biocompatible glass con
taining Cu or other trace element and useful in this invention

O.6
12.0

tion of, for example, faster reacting fibers or particles in
combination with slower reacting fibers or particles; or the
are shown in Table 5.
45 selection of Ca-containing fibers or particles with Ca-free
fibers or particles. One can therefore select standard compo
TABLE 5
sition components and combine them with non-standard
composition components to effectively customize or dope the
Weight Percent Composition of Phosphate
overall composition for the application presented, or for the
Based Biocompatible Glasses
50 host’s particular needs. Alternatively, hollow spheres con
Glass
taining a growth factor or drug for delivery to the host can be
ID Na2O KO CaO MgO B.O. POs Li2O SrO CuO
incorporated with the compressible body, ointment, cream,
P-1
3.8
S.8 27.5
2.5
O.O 6O.O
O.O.
O.O.
O.4
glue, or Suture.
P-2
9.2
9.3 27.5
O.O.
O.O S3.5
O.O.
O.O.
O.S
The method of making the glass is not narrowly critical to
P-3
7.8 11.8 17.O 76
O.O SS.2, O.O.
O.O.
O.6
P-4
7.8 11.8 17.0 7.6 0.0 55.2 0.0 00 0.6 55 the invention. By way of example, in preparing the glass,
P-5
6.6
8.9 21.9 O.O
41
58.O O.O.
O.O.
O.S
individual analytical reagent grade components are weighed,
P-6
10.5
O.O 230
O.O
4.O 611
11
O.O.
O.3
mixed thoroughly, and melted in a platinum crucible attem
P-7
8.0
3.7
1.5
O.O
1.8 78.1
O.O
6.7
O.2
peratures ranging from 900 to 1500° C. for approximately one
to four hours. The melt is then quenched, for example, on a
These phosphate-based formulations demonstrate situa- 60 steel or copper plate to form glass that can be ground into
tions where it is advantageous to include at least two of the particulates of a desired size. The material of preferred com
alkali oxides LiO, NaO, K2O, and/or Rb-O in a cumulative positions when in the form of a melt can easily beformed into
fibers or particles. Fibers can either be pulled by hand directly
concentration of between about 5 and about 25 wt %, such as
from the melt or pulled through bushing by a rotating drum.
between about 8 and 20 wt %. As noted above, it has been
discovered to be advantageous to include two or more Such 65 The biocompatible material may be glassy, glass ceramic,
alkali compounds in order to reduce the tendency for crystal or ceramic in nature. However the glassy state is preferred in
lization, which ultimately improves the workability and this invention because, generally speaking, glassy materials
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are stronger and more chemically homogeneous than their
crystalline or partially crystalline counterparts of the same
composition. In this description, the term 'glass” is used to
include materials which are entirely glassy as well as mate
rials which are part glassy and part crystalline. It is therefore
preferable that the biocompatible material is substantially
glass in that less than about 5 wt %, more preferable less than
1 wt %, of the component material is crystalline material. The
glass used in many embodiments of the invention, consistent
with the foregoing description, are at least 99 wt % an amor
phous or non-crystalline solid, for example made by fusing a
mixture of oxides such as one or more of SiO, BO, POs
(known as glass forming oxides) with basic oxides Such as the
alkali and alkaline earth oxides, along with the optional one or
more trace element compounds such as Cu compounds. In an
alternative embodiment, the fibers or particles include glass
ceramics fibers that contain both glassy and crystalline
regions which in many respects function in the same manner
as a fiber that is completely (100%) non-crystalline. The
fibers or particles may alternatively be pre-reacted biocom
patible glasses such as glass fibers or particles pre-reacted to
have a thin Surface layer of hydroxyapatite.
Example 1

18
dressing looks like a normal scab. The scab generated by the
dressing reacting with the underlying tissue appears to have
formed a beneficial temporary barrier. In FIGS. 13 and 14, the
scab can be seen peeling away from the wound as the wound
closes. The scab on the control side in FIGS. 13 and 14 is still

dark in color and dry.
The area of each wound was measured periodically, and the
average area for each control and wound covered with dress
ing was calculated and plotted vs. time. The graph in FIG. 15
10

15

25

The dressing comprising a compressible body of loose
glass-based fibers of FIG. 1 was prepared from glass of com
position 53 wt % BO, 20 wt % CaO, 12 wt % KO, 6 wt %
NaO, 5 wt % MgO, 4 wt % POs. As shown in FIG. 2, there
were some residual beads (microspheres) of that are formed
as part of the process for forming fibers. The diameter of the
fibers ranged from of about 300 nm to about 2000 nm, as
shown in FIG. 3. The microspheres were much larger in
diameter and ranged from approximately 20 microns to about

30

300 microns as shown in FIG. 2.
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The compressible body of FIG. 1 was used in an experi
ment to fill a cutaneous defect in a rat. It was shaped by hand
to forma disk about 15 mm in diameterandabout 2 mm thick.

This cylinder was placed in a wound as shown in FIG. 4. The
rats were Fisher 344 rats having an age between 9 and 11
weeks and a weight between 200 and 300 grams. Prior to
implantation, the dressings were washed twice with ethyl

40

alcohol and heat sterilized at 250° C. for 2.5 hours in a small

box furnace. For application, the back of the rat was shaved,
sterilized with iodine, and washed with 70% ethanol. Each rat

45

was anesthesized with a mixture of isofluorine and medical

grade oxygen. After application of the dressing, 0.1 mL of
Penicillin G Procaine was injected into each thigh of the ratto
prevent infection. The rats were placed on a heating pad in a
cage with fresh air during recovery.
FIGS. 5 through 10 show a representative set of images
showing the healing progression of a control wound (left side)
and a wound covered with the compressible body (right side).
The day 0 image clearly shows the wound covered with the
dressing (white area) that fills the entire wound. The two
wounds were monitored for about three weeks as shown by
the images of FIGS. 5through 10, which show that the wound
covered by the dressing healed at approximately the same rate
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between the two vertical dotted lines in FIG. 16. FIG. 20

shows the Subcutaneous tissue that is not completely healed
along with some reacted glass bead. There are no visible areas
of dead or unhealthy looking tissue, and hair along with fat
deposits are present in the regrown tissue similar to the adja
55

cent recovered tissue as shown in FIG. 17.

In view of the above, it will be seen that the several objects
of the invention are achieved and other advantageous results
attained.

as the control wound.

FIGS. 11 through 14 show a few selected higher magnifi
cation images to illustrate the benefits of the dressing. The
control (no dressing) is on the left and the wound covered with
the fiber dressing is on the right. FIG. 11 shows the open
wounds on day 0. The wounds are moist and the exposed
tissue appears healthy. FIG. 12 shows the wounds after four
days, revealing that the tissue of the control wound was dried
and dark grey in appearance while the side covered with the

shows there was little difference between the closure of the

control wound and the dressing-covered wound. However,
the dressing-covered wound had a barrier protecting it from
its surroundings, and while possibly slowing the wound clo
sure initially, the barrier likely helped keep out harmful
pathogens.
After 22 days, the animals were sacrificed, and the wounds
and Surrounding tissue was recovered from each animal for
histological analysis. FIG. 16 is a representative histological
section from the wound covered with dressing. The glass
fibers were either dissolved in the body fluids, or removed as
the scab peeled away, as they were not visible in these photos.
Glass microspheres that had reacted in the animal that were
left behind from the dressing are shown in FIGS. 18, 19 and
20. However, the microspheres seen in FIGS. 18 and 19 did
act as an indicator of where the fibers were prior to wound
closure. The wound dimensions were approximated by the
presence of reacted microspheres left behind in the wound.
The approximate original wound size (~1 cm in diameter) has
been labeled in FIG. 16, and significant healing is evident.
FIGS. 16 through 20 all show glass microspheres that
reacted in-vivo to form hollow microspheres of hydroxyapa
tite. Previous experiments have proven that the glass of the
disclosed composition reacts to form hydroxyapatite when
placed in an in-vivo environment. FIG. 18 is a magnified view
of 17, and a blood vessel is seen adjacent to a reacted glass
bead. This vessel appears to be evidence that boron, which is
released from the glass as it reacts in-vivo, produced an angio
genic effect in the animal and enhanced the wound healing
process. There was also a vessel close to two of the reacted
microspheres in FIG. 19 as indicated by the arrow, and there
were also three vessels next to the reacted microspheres in
FIG. 20 (circled), as indicated by the arrow.
From the histological images present in FIGS. 16 through
20, the tissue that was generated in the presence of the dress
ing appears similar to the Surrounding natural tissue. After 22
days, the dermal and epidermal layers were completely
healed, and the subcutaneous tissue (shown in FIG. 20) had
almost completely healed as the unhealed section of Subcu
taneous tissue is indicated by the short horizontal arrow

60

When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles “a”, “an',
“the' and “said are intended to mean that there are one or

65

more of the elements. The terms “comprising”, “including
and “having are intended to be inclusive and mean that there
may be additional elements other than the listed elements.
AS Various changes could be made in the above composi
tions and methods without departing from the scope of the
invention, it is intended that all matter contained in the above
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description and shown in the accompanying drawings shall be
interpreted as illustrative and not in a limiting sense.

20
one or more alkali oxides selected from the group consist
ing of LiO, NaO, KO, and RbC); and
one or more alkaline earth oxides selected from the group
consisting of MgO, SrO. BaO, and CaO.
12. The dressing of claim 1 wherein the glass-based fibers

The invention claimed is:

1. A flexible dressing for wound care management com
prising:
a three-dimensional compressible body comprising loose
biocompatible glass-based fibers comprising from about

comprise:

40 to 80 wt % B.O.;

at least about 25 wt % of the fibers have a diameter between

about 200 nm and about 4000 nm, and a length:diameter
aspect ratio of at least about 10.
2. The dressing of claim 1 wherein the glass-based fibers
comprise no more than 18 wt % SiO.
3. The dressing of claim 1 wherein the glass-based fibers
comprise less than 0.1 wt % SiO.
4. The dressing of claim 1 wherein the compressible body
in its uncompressed state has a porosity of at least about 30%

10
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prising:

a three-dimensional compressible body comprising loose
biocompatible glass-based fibers comprising from about
40 to about 80 wt % B.O.;
at least about 25 wt % of the fibers have a diameter between
about 200 nm and about 4000 nm, and a length:diameter

by volume.

5. The dressing of claim 1 wherein the compressible body
in its uncompressed state has a porosity between 40 and 75

vol. 96.

6. The dressing of claim 1 wherein the body further com
prises glass components selected from the group consisting of
beads, microspheres, regular particles, irregular particles, rib
bons, flakes, and hollow spheres.
7. The dressing of claim 1 wherein the compressible body
has a surface area/bulk body volume in the relaxed, uncom
pressed state of the body of between about 1 and about 2000
cm', such as between about 50 and about 500 cm'.
8. The dressing of claim 1 wherein the compressible body
has a Surface area/bulk body Volume in the relaxed, uncom
pressed state of the body of between about 50 and about 500

aspect ratio of at least about 10;
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9. The dressing of claim 1 wherein the glass-based fibers

a concentration between about 0.05 and 10 wt % per trace
element chemically dissolved in the biocompatible material.
10. The dressing of claim 9 wherein the one or more trace
elements are homogeneously dispersed within the fibers and
are thereby adapted to be time-released during biodegrada
tion of said fibers.

11. The dressing of claim 1 wherein the glass-based fibers

comprise:

from about 40 to about 80 wt % B.O.;

between about 1 and about 25 wt % glass-based particles
comprising a glass-former selected from the group con
sisting of P-Os. SiO2, B2O, and combinations thereof,
and having a diameter between about 10 and about 500
um, wherein said particles are distributed among the
fibers.

30

cm'.

further comprise one or more trace elements selected from the
group consisting of Ag, Cu, F, Fe, Mn, Mo, Ni, Sr. and Zn in

from about 40 to about 80 wt % B.O.;
one or more alkali oxides selected from the group consist
ing of Li2O, Na2O, K2O, and Rb2O in a cumulative
concentration from 5 to 25 wt %; and
one or more alkaline earth oxides selected from the group
consisting of MgO, SrO. BaO, and CaO in a cumulative
concentration from 1 to 30 wt %.
13. The dressing of claim 1 wherein the compressible body
comprises fibers of a first composition and fibers of a second
composition distinct from the first composition.
14. A flexible dressing for wound care management com
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15. The dressing of claim 14 wherein the glass-based par
ticles are microspheres.
16. The dressing of claim 1 wherein the fibers comprise Cu
in a concentration between about 0.05 and 10 wt % chemi
cally dissolved in the biocompatible material.
17. The dressing of claim 1 wherein the compressible body
in its uncompressed state has a thickness between about 5 mm
and about 30 mm.

18. The dressing of claim 1 wherein the compressible body

40

is a layer.

19. The dressing of claim 1 wherein the compressible body
is a layer having a length and a width which are between about
5 and about 30 times the thickness of the body.
20. The dressing of claim 1 wherein the glass-based fibers
further comprise POs in a concentration of 0 to 10 wt %.
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